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ABSTRACT 
The development of a drug delivery system (DDS) is essential in many cases to remedy the 
limitations of free drug molecules.  Silica has been of great interest as a DDS due to being more 
robust and versatile than other types of DDS (e.g. liposomes).  Using ibuprofen as a model 
drug, we investigated bio-inspired silica (BIS) as a new DDS and compared it to mesoporous 
silica (MS); the latter have received much attention for drug delivery applications.  The BIS is 
synthesised under benign conditions and without the use of hazardous chemicals, which 
enables controllable in situ loading of drugs by carefully designing the DDS formulation 
conditions.  Here we systematically studied these conditions (e.g. chemistry, concentrations 
and pH) in order to understand BIS as a DDS and further achieve high loading and release of 
ibuprofen. Drug loading into BIS could be enhanced (up to 70%) by increasing the 
concentration of the bioinspired additive.  Increasing the silicate concentration increased the 
release to 50%.  Finally acidic synthesis conditions could raise loading efficiency to 62% while 
also increasing the total mass of drug released.  By identifying ideal formulation conditions for 
BIS, we were able to produce DDS that were able to release fivefold more drug per weight of 
silica when compared with MCM-41. Biocompatibility of BIS was also investigated which 
found that, although ~20% of BIS was able to pass through the gut wall into the blood stream, 
it was non-haemolytic (~2% haemolysis at 500 µg ml-1) when compared to MS (10% 
haemolysis at the same concentration). Overall for DDS, it was clear that BIS has several 
advantages over MS (ease of synthesis, controllability and lack of hazardous chemicals) as well 
as being less toxic, making BIS a real potentially viable green alternative to DDS.  
Keywords:  
Nanomaterials, nanomedicines, pharmaceuticals, cytotoxicity, biomedical devices.  
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1. INTRODUCTION 
Drug molecules currently on the market, while effective, can have a whole range of 
limitations which reduce the efficacy of the drug.  Some limitations include poor solubility, in 
vivo degradation and short systemic circulation times 1.   Due to these factors, in order to 
achieve efficacy, drugs may require higher doses, which can result in higher toxicity 1.   One 
method of improving drug efficacy is by developing drug delivery systems (DDS) 2.  Aside 
from the obvious potential medicinal benefits of DDS, there are also large economic benefits 
to be gained as new DDS take significantly less time and investment to develop than a new 
drug molecule (3-4 years and approximately $20-50 million for DDS 1 vs $500 million and 10-
12 years for a new drug3). 
Many materials have been investigated for the use of DDS, e.g. liposomes, polymeric 
QDQRSDUWLFOHV HJ GHQGULPHUV DQG ³KDUG´ QDQRSDUWLFOHV PDLQO\ FRQVLVWLQJ RI PHWDOV HJ
gold), metal oxides (e.g. iron oxide, titanium oxide and silica) or carbon 4-6.  However, 
relatively few DDS are currently on the market 7.  The main limitations for any DDS becoming 
a clinical product are the long regulatory journey coupled with issues with biocompatibility, 
efficacy and manufacturing processes.  Briefly, a DDS must first be proven to work and be safe 
in vitro and then in vivo, manufacture should be straightforward and it should provide 
significant benefits over risks before it can gain support from patents and financial backing.  
Next human clinical trials are carried out and if these are passed then the product will go on to 
become commercialised 7.  This long, multi-step process can create obstacles for new DDS and 
results in the failure of many of them.  Due to the high failure rate of DDS there is huge potential 
for new developments in this field. 
Here we focus on silica as a DDS because there has been increasing interest in the use 
of silica nanoparticles for the purpose of drug delivery since 2001, when Vallet-Regi, et al., 
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described the effective loading and release of ibuprofen from a type of mesoporous silica 
nanoparticle (MCM-41) 8.  The successful use of a silica DDS over other systems (e.g. 
liposomes) has been attributed to its thermal and chemical stability as well as versatility 
compared to conventional drug delivery systems 9,10 11,12.  Further, silica offers a versatile 
platform for functionalisation with biomolecules in order to tailor drug release as well as 
targeting the delivery. One of the most common methods of controlling drug release is through 
functionalising silica to create stimuli-responsive DDS.  This opens up a wide range of external 
stimuli which can be used to manipulate these materials, ranging from magnetism, ultrasound 
and light, to the more conventional, temperature and pH 13-16. The functionalisation has also 
shown promise in targeted drug delivery. For example, an interesting avenue is using silica 
functionalised with cell penetrating peptides for targeted delivery directly into cytoplasm.17 
Silica can be functionalised with various chemical groups, making it compatible with a 
range of drugs. Examples of various drugs investigated with silica range from anti-
inflammatories like ibuprofen or aspirin to antibiotics such as gentamicin and erythromycin, 
anti-malarials and anticancer drugs such as doxorubicin and campothecin 8-10,18-27. While a gold 
coated silica product (Auroshell28) is in the first stage of development to be available as an anti-
cancer agent, there are currently no silica based drug delivery systems on the market, despite 
the fact that  MS showed some promise as effective DDS nearly 15 years ago.  This delay is 
due to several limitations including long and laborious synthesis (synthesis of MCM-41 can 
take between 10 and 146 hours29-32), the use of harsh chemicals, toxic surfactants, hazardous 
precursors and harsh conditions (extremes of temperatures and pH 31).  These imply that drug 
loading can only occur post-synthesis, which adds another step (and extra time) to the synthesis 
of this type of DDS.  Therefore, a greener, economical, scalable and safer method of 
synthesising silica with potential for in situ drug loading would be highly favourable.  
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Biomineralisation of silica is observed in several species of aquatic unicellular 
organisms, such as diatoms (a class of algae) 33, as well as in more complex organisms, such 
as some sponge species and even in some plants 34-36.  It was found that specific proteins and 
biomolecules were involved in the condensation of biosilica, such as silicatein and silaffin 34-
36
.  By understanding the chemistry and the role of these biomolecules, we have developed 
analogues of these biomolecules ³DGGLWLYHV´, typically amines) which have been shown to 
rapidly condense silica under benign conditions 37,38.  As such, this has enabled the discovery 
of bio-inspired silica (BIS) which can be controllably synthesised at room temperature, at 
neutral pH, in water and within 5 min 39.  This also opens the possibility of in situ drug loading, 
thus allowing a one step, green, DDS formulation 40. Further, amine-ibuprofen interactions 
have been reported to be favourable for drug delivery 41-43, which provides another potential 
benefit of BIS over MS: a possible additional function of the amine additives.   
As yet only five papers have been published on the use of BIS synthesis for drug 
delivery applications (including one from our group 40), suggesting a vast potential for future 
research.  Li, et al, utilised a so-called ³ELRPLPHWLF´V\QWKHVLV URXWHKRZHYHU WKLVPHWKRG
retained all the issues of synthesising MCM-41 (i.e. long synthesis time, high temperatures and 
requirement for calcination) 44 .  Begum et al. made use of surfactants to create porosity, thus 
their system still requires an energy intensive calcination step as well as post-synthesis drug 
loading 45.  Sano et al. designed a drug molecule which had the dual function of 
pharmacological activity and silica condensation ability (not all drug molecules will have this 
dual ability) meaning that the system was limited to only a small set of drug molecules 46.  
Lechner et al. linked their cargo molecule to a silica condensing peptide; however, they were 
not able to fully control drug release.  Conjugating peptide with drug has many other issues, 
such as loss of drug activity, use of hazardous chemicals and also an extra synthesis step47.  
Preliminary work from our group reported the green synthesis of silica with in situ drug loading 
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of calcein (a hydrophilic drug-like molecule) 40.  This synthesis required no calcination and the 
amine additive was separate from drug molecule.  BIS did not show any significant toxic effects 
to either fibroblasts or human monocytes in the resting state, even at high silica concentrations. 
However, mesoporous silica particles showed substantially reduced cell viability, even at low 
concentrations. For example, the silica concentration required to reduce cell viability to 50% 
(IC50) was 5-10 times more for BIS than MCM-41. Further, BIS did not induce secretion of 
inflammatory cytokines at the concentrations proposed for use in DDS.40 From these results, it 
is evident that despite the use of amine additives, the BIS are safe and do not cause concerning 
cytotoxicity.  
In the present study we aimed to further extend BIS to a pharmaceutically active drug 
molecule (ibuprofen) and create a DDS formulation which, through carefully investigating and 
understanding the formulation chemistry, would have the ability to control the loading and 
release of pharmaceutically active drugs.  Ibuprofen was chosen since it is a commonly used 
model drug for DDS development due to its small molecular size (1.0 x 0.6 nm2) 8, stability 48, 
ease of detection (UV absorbance at ~220 nm), and available literature on ibuprofen-silica 
systems for comparison. The main aim of this research is to primarily understand in situ drug 
loading into the BIS system.  Specifically, we plan to determine predictive rules, investigate 
the effects of amine additive, drug interactions and silica chemistry on DDS performance (drug 
loading and release profiles).  Further, in order to make BIS a viable DDS, it should exhibit 
similar or improved loading and release profiles for ibuprofen when compared to the 
competitor MCM-41 based DDS.   
 
2. MATERIAL AND METHODS 
2.1. Chemical Reagents 
7 
 
All reagents were purchased from Sigma unless otherwise stated. 
Acetronitrile (+3/&3OXV, ammonia (NH3, DQK\GURXV), anhydrous sodium 
sulphite (97%), ammonium molybdate ·4H2O, calcium chloride hexahydrate (USP testing 
specifications), concentrated hydrochloric acid, diethylenetriamine (DETA) (99%), 
dinitrophenol (  (DNP), 'XOEHFFR¶V 3%6 formic Acid ( , glucose (), 
heparin, hexadecyltrimethylammonium bromide (CTAB), hydrochloric acid solution 1M (HCl, 
Fisher), ibuprofen (, Immu-mount,  magnesium sulphate heptahydrate, oxalic acid 
·2H2O ( pentaethylenehexamine (PEHA) (technical grade), potassium chloride 
(, phosphate buffered saline (PBS) (tablets pH 7.4), poly(allylamine hydrochloride) 
average Mw ~17,500 (PAH), poly(fluorescein isothiocyanate allyamine hydrochloride) 
(Poly(allylamine hydrochloride) : Fluorescein isothiocyanate 50:1), potassium phosphate 
monobasic, sodium chloride , sodium metasilicate pentahydrate (technical) (Fisher), 
sulphuric acid (98%), tetraehylenepentamine (TEPA) (Acros organics), tetraethoxysilane 
(TEOS) (99.999% trace metals basis ), Triton X-100 (laboratory grade). 
 
2.2. In situ drug loading into BIS and drug release 
To a solution of sodium metasilicate in deionised water a solution of amine additive (in 
water) was added followed by an ibuprofen solution (in 70% ethanol).  Then a known volume 
of 1M HCl (the volume of HCl required varied depending on the amine additive used) was 
added to reduce the pH of the solution to the desired pH (pH 7, unless otherwise stated).  The 
concentrations of the reactants in the final solution were 30mM of sodium metasilicate, 1mg 
ml-1 PAH and 1mg ml-1 ibuprofen, this ratio was termed 1:1:1.  For a 50ml batch of 1:1:1, 
0.3182g sodium silicate, 0.05ml of PAH and 0.05g of ibuprofen were used. When synthesising 
BIS with other amines (DETA, TEPA and PEHA), a molar ratio of [Si]:[N] of 1:1 was used.  
This equates to 0.05155g of DETA, 0.05678g of TEPA and 0.05809g of PEHA for a 50ml 
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batch.  Once acid was added, silica precipitated within seconds and the solution was left for 5 
minutes before being centrifuged at 8000 rpm for 15 minutes in order to stop the reaction.  The 
supernatant was stored at 4oC in order to determine the drug loading efficiency (% of drug 
which was loaded into the silica) and drug content (% weight of drug in the silica-drug 
complex) via the method described in section 2.4.  The silica pellet was resuspended, washed 
in deionized water and centrifuged, twice more (no detectable drug was observed in these 
supernatants) and finally dried at 45 oC for at least 5 hours. 
Once dried, 10 mg of the silica was suspended in 1.4ml of PBS (pH 7.4) and incubated at 
37 oC to measure the drug release.  At each time point (1, 3, 5, 7 and 24 hour time points), 
samples were centrifuged at 8000 rpm for 15 minutes and 1 ml of the supernatant was used for 
HPLC analysis and replaced with fresh PBS in order to satisfy the perfect sink conditions for 
the determination of the diffusion parameters.  Release is expressed as the % of the loaded drug 
which has been released from 10mg of silica.  Each sample was prepared in triplicate and 
release profiles were measured from each sample in triplicate. 
2.3. Synthesis of MCM-41 and post synthesis drug loading 
MCM-41 was synthesised by first dissolving CTAB in 300 ml of 25 % ammonia at 35 oC.   
While stirring, 20 ml of TEOS was slowly added.  This solution was then stirred for 3 hours 
and then aged for 24 hours at room temperature in a closed container to allow silica to form.   
The product was then vacuum filtered and washed with 1 litre of distilled water and finally 
dried overnight at 85 oC.  To remove the surfactant (CTAB), MCM-41 was calcinated at 500oC 
for 5 hours.   This was based on previously published methods 12. 
To load drug, 10mg of MCM-41 was immersed in a 1 mg ml-1 solution of ibuprofen (in 
70% ethanol) at 37 oC overnight.   Samples were centrifuged at 8000 rpm for 15 minutes and 
the supernatant was removed (and supernatant drug concentration was measured to determine 
loading efficiency) and replaced with fresh PBS for a release experiment. At each time point 
9 
 
samples were centrifuged at 8000 rpm for 15 minutes and 1ml of the supernatant was taken for 
HPLC analysis and replaced with fresh PBS. 
2.4. Drug detection via high performance liquid chromatography (HPLC) 
Drug loading and release were determined via an HPLC analysis method.  A DIONEX 
system was used with an auto-sampler (GINA50), a pump (P580) and variable wavelength 
detector (UVD170S), along with an ACE 5 C-18 column (150X4.6 nm with 5 µm particle size) 
at room temperature.  An isocratic reverse phase HPLC method was used with 30 µl injection 
volume and a mobile phase of acetonitrile: 0.1% formic acid (70:30) at a flow rate of 1ml min-
1
.  Ibuprofen retention time was approximately 4.7 minutes and was detected at a wavelength 
of  QP Ȝmax wavelength of ibuprofen).  Data were collected using Chromeleon V6.80 
software and peaks were integrated to determine drug concentration.  Data were fitted with a 
single exponential equation (Eq. 1) where Y0 is the final % release, A is a constant and R0, is 
the slope.  By multiplying A and R0 the maximum rate of release (% release per hour) was 
deduced. 
      ݕ ൌ ଴ܻ ൅ ܣ݁ோబ௑   [Eq. 1] 
2.5. Materials characterisation 
Silica samples were characterised using nitrogen adsorption in a micromeritics ASAP 2420 
Accelerated Surface Area and Porosimetry system.  Samples were first weighed and degased 
in optimum pressure and temperature conditions (120 oC).  They were then held at the boiling 
point of nitrogen and evacuated allowing for nitrogen gas to enter the sample tubes while the 
pressure was monitored.  Analyses of the data included BET (Brunauer Emmett Teller  49) 
theory, used to characterise the surface areas of the silica particles, and the BJH (Barrett Joyner 
Halenda 50) theory which allowed for the characterisation of the silica pore size distributions.  
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Silica samples were imaged by scanning electron microscopy (SEM) using a Hitachi 
SU6600 field electron-SEM.  Samples were mounted on sample holders using sticky carbon 
tape and then gold splutter coated under vacuum to prevent the charging of the sample.  
Micrographs were taken using a 20kV potential difference and a working distance of 8.7mm. 
 
 
2.6. Measuring movement of silica across the gut wall 
Rats (200-250g, male, Sprague Dawley) were anesthetised via intraperitoneal injection 
with pentobarbitone (60mg/kg) and sacrificed for the experiment.  The small intestine was 
removed and washed through with 37oC Krebs solution (made from distilled H2O, 16.09% 
(w/v) NaCl, 1.1% (w/v) KCl, 0.22M KH2PO4, 2.74% (w/v) MgSO4.7H2O, 0.12M 
CaCl2.6H2O).  Intestines were then inverted and bathed in Krebs solution, ensuring 37oC 
temperature was kept constant.  Small sections of gut (~5-6 cm) were cut and tied closed at one 
end with thread, filled with 1ml of fresh Krebs solution, and then the open end was also tied 
closed. 
In order to verify the health of the sections of gut, a control experiment was set up which 
measured the passage of glucose across the gut wall.  Sections of gut were either immersed in 
6ml of 1mM glucose solution or in 1mM DNP (dinitrophenol) solution (to inhibit the active 
transport of glucose 51) for 15 minutes at 37oC before a glucose solution (to make a final 
concentration of 1mM) was added.  Sections of gut were then incubated at 37oC for an hour, 
before being cut open and their contents removed.   Glucose concentrations were measured by 
using a Glucose (gluc-pap) assay kit purchased from Randox.   
 To measure the passage of silica through the gut wall, fluorescent silica was prepared 
using the same method in section 2.2 except that PAH-FITC was used as the amine additive, 
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thus creating fluorescently labelled silica.  Fluorescence was measured on a RF-530IPC 
fluorometer at excitation wavelength of 495nm, and emission wavelength of 515nm.  Tubes of 
inverted rat gut sections were incubated in 1 mg/ml silica solution (in Krebs) or 1mg ml-1 silica 
solution and 1mM DNP for an hour at 37oC.  Gut sections were then cut open and contents 
removed and the fluorescence measured; the sections were then fixed in a formalin solution 
(neutral buffered 10%) for 30 minutes followed by two PBS (pH 7.4) washes.  The inside and 
outside surfaces of the gut sections were then imaged using a Carl Zeiss Axio Imager Z1 with 
10x/0.30 lens.   Sections of gut were mounted either by stretching the gut and pinning the edges 
or compressing gut sections under Immu-mount and coverslips. 
 
2.7. Haemolytic activity of silica 
To measure the haemolytic activity of silica, rats (Sprague Dawley) were bled and the blood 
was stabilised with heparin (100 µl of 1000 units ml-1).  4ml of heparin stabilised blood was 
GLOXWHGZLWKPORI'XOEHFFR¶V3%6DQGFHQWULIXJHGDWJIRUPLQXWHV7KHVXSHUQDWDQW
was carefully removed and the blood was washed five times with 'XOEHFFR¶V3%6D-PBS).  
After the last wash the red blood cells (RBC) were diluted with 40ml of D-PBS.  0.2ml of 
diluted RBC were then added to 0.8ml of silica suspension at the desired concentration to make 
a final silica suspension.  Positive and negatives controls were set up by adding 0.2ml of RBC 
to either 0.8ml D-PBS or 0.8ml of 0.2% Triton X-100 respectively.  All samples were prepared 
in triplicate and briefly vortexed before being left static at room temperature for 4 hours.  
Samples were then vortexed again and centrifuged at 10,000g for 2 minutes.  10µl of 
supernatant was used to the absorbance of haemoglobin using an anthos2020 plate reader at 
577nm with a reference wavelength of 655nm.  Haemolysis was calculated as % haemolysis = 
[(sample absorbance ± negative control)/(positive control ± negative control)] x 100 52. 
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3. RESULTS AND DISCUSSION 
In order for BIS to be developed as an effective DDS, one must understand the synthesis 
chemistry and the mechanisms that dictate the loading and release of drug molecules from the 
system.  There has been little published on the loading mechanics of the BIS system and it has 
been speculated,  but not proven, that embedded amine, originally employed to facilitate silica 
condensation, also helps to functionalise the silica 40.  If this is the case then the BIS DDS can 
be synthesised, functionalised and drug loaded all in one step which is a vast improvement on 
the long multi-step process involved in MS. All these possibilities were investigated herein. 
3.1. The effect of the amine additive on the loading and release of ibuprofen 
The effect of the choice of amine additive for the synthesis of BIS upon its ability to load 
and release calcein (a non-pharmaceutically active EXW³GUXJ-OLNH´molecule) has previously 
been reported40.  As these effects are drug specific, we investigated them for an active drug 
molecule (ibuprofen) in the BIS system and compared earlier results for calcein, with those for 
ibuprofen.   
In order to screen most suitable systems, four additives were investigated± three small 
amines and one polyamine.  These were chosen based on their silica precipitation performance 
and previous investigations into BIS 37,38,40,53.  We measured the loading efficiency (amount of 
drug loaded on DDS when compared to the concentration used for loading), drug content in 
the DDS (amount of drug loaded per weight of DDS) and total amount of drug released (mg 
drug/10 mg DDS). Diethylenetriamine (DETA), a small amine, was immediately excluded for 
use as it had a loading efficiency of only <5% (Figure 1A).  The other amines used were 
pentaethylenehexamine (PEHA), tetraethylenepentamine (TEPA)) and poly(allylamine 
hydrochloride) (PAH) and they exhibited loading efficiencies of 20-30%, while MCM-41 
showed ~40% loading efficiency (Figure 1A).  These differences between BIS and MCM-41 
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are likely due to the different methods by which the drug was loaded into these two types of 
silica.  For BIS, ibuprofen was loaded in situ and so the drug would have been entrapped within 
the silica particles, followed by some surface physisorption.  With MCM-41, only post-
synthesis loading was possible and so drug loading was entirely reliant on physisorption (hence 
surface area and porosity is important in this system).   
Focussing on drug release from these DDS, despite having loading efficiencies similar to 
BIS-PAH, BIS-TEPA or BIS-PEHA released <2% of loaded drug and as such these amines 
must also be discarded (Figure 1 B and C).  Approximately 22% of loaded ibuprofen was 
released from BIS-PAH, compared to the 39% released from MCM-41 (Figure 1B and Table 
S1). The release data appeared to fit well using a single exponential equation with >0.9 R2 
values in all cases (Table S1).  The fitting showed that BIS-DETA, BIS-TEPA and BIS-PEHA 
all had a very low release rate (Figure 1B and C).  However, the rates of release (Table S1) 
from MCM-41 and BIS-PAH were similar (15 and 17% per hour respectively). 
The loading efficiency of drug on MCM-41 was found to be 41%, while the loading 
efficiency for BIS-PAH was 23% (Figure 1A).  Despite this, MCM-41 released around half the 
amount of drug when compared to BIS-PAH (0.12mg compared to 0.28mg for 10 mg DDS, 
respectively).  This implies that for a dose of 1 mg of ibuprofen, a patient would have to take 
~83 mg of MCM-41 compared to only ~54 mg of BIS-PAH.  High doses of MCM-41 silica 
can result in serious toxicity issues unlike BIS40,52, which highlights a key benefit of using BIS.   
The differences in release profiles between BIS synthesised with the different amines are 
likely to be due to the porosity and morphology characteristics of the silica synthesised (Figure 
1D and S1B).  Adsorption of drugs is a function of pore size, pore volume and surface area; 
particle size does not have any impact on release but rather pore morphology.54,55     In the case 
of MCM-41 (a mesoporous silica), it is generally accepted that porosity is a major factor in 
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controlling the release of drugs, and so further investigation was needed as to whether this was 
the case for BIS 43,56,57.  BIS-DETA, TEPA and PEHA all have a very small pore volume (~0.1 
cm3/g) and low surface areas (~20-40 m2/g), see Figure 1D, The pore volume and surface area 
for BIS-PAH (0.74 cm3/g and of 129 m2/g respectively) were higher than that of silica 
synthesised with the other three amines.  This suggests that silica particles synthesised with 
any of the small amines were dense when compared to BIS-PAH, which explains the higher 
release from BIS-PAH within the BIS series.   These observations explain why BIS-DETA, 
TEPA and PEHA samples exhibit poor drug loading/release when compared with BIS-PAH.  
Interestingly, MCM-41 has a much larger surface area (989 m2/g) than any of the BIS, but it 
demonstrated loading efficiency comparable with BIS-PAH.  Scanning electron microscopy 
(SEM) revealed that BIS-PAH particles were fairly uniform in shape and sizes exhibiting a 
range between 72±17 nm and 78±18 nm (Figure S2A & B), without and with the drug, 
respectively, thus suggesting that the presence of the drug did not affect the particle sizes 
significantly. On the other hand, MCM-41 samples used herein were not only very large in 
comparison (3340±1013 nm, Figure S1A & B) but also non-uniform with large variations in 
sizes and shapes. Further, it is interesting to note that despite the differences in particle sizes 
between MCM-41 and BIS-PAH, the amounts of drug released were often comparable. At this 
point in time, a direct comparison between these two DDS is not possible simply based on 
SEM results because of their distinctly different drug loading mechanisms and further analysis 
in future is necessary.  
Along with porosity altering the release of ibuprofen, it has been reported that amine-
ibuprofen interaction is important in loading 40,42,58. Since BIS-TEPA and BIS-PEHA showed 
over 30% drug loading efficiency, it is possible that the amine additives facilitate ibuprofen 
loading through favourable amine-drug interactions as reported elsewhere41-43,58 but they also 
form non-porous silica by fully encapsulating ibuprofen within the dense silica particles thus 
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resulting in very low release.  PAH, however, allows ibuprofen loading through favourable 
interactions with amine groups and release occurs through the silica pores. These observations 
are consistent with the literature where it has been reported that these small amines lead to the 
formation of dense and non-porous silica, while PAH forms porous silica 37,38.  
3.2. Altering reactant concentrations to understand the silica-drug system 
The main aim here is to understand the DDS and investigate how controllable it is with 
ibuprofen so that this knowledge can be implemented for other drugs. As such, our next step 
was to study the effects of reaction chemistry on DDS performance. There had been some 
evidence that altering reactant concentrations can alter the loading and release profiles of 
calcein from BIS synthesised with PAH 40; however, the reasons behind this effect were not 
fully investigated.  Therefore, a systematic approach by varying synthesis conditions and 
evaluating their effects on drug loading and release has been taken while keeping the starting 
concentration of ibuprofen in the reaction mixture constant (1 mg ml-1). 
Figure 2A and Table S2 show that for MCM-41 (as reported in the section above), the 
loading efficiency was ~40% and the drug content was ~3 wt%.  The loading efficiency and 
drug content for the 1:1 BIS-PAH sample (30mM solution of sodium metasilicate and a 1mg 
ml-1 solution of PAH) were ~22% and 13 wt%. When the concentrations of silicate and PAH 
were doubled (2:2) there was a doubling of ibuprofen loading efficiency (Figure 2A).  This was 
attributed simply to more silica being formed (Table S2) since the drug content did not change 
(Figure 2A).  When only the silicate concentration was increased, but the PAH concentration 
was kept at 1mg ml-1 (2:1), there was a slight increase in ibuprofen loading efficiency (Figure 
2A) but drug content remained unchanged which was attributed simply due to an increased 
silica yield (Table S2).  Producing more silica means that more ibuprofen was loaded (and so 
less was wasted by being left in the reaction mixture).  Interestingly, when a synthesis ratio of 
1:2 (increasing PAH concentration but maintaining silicate concentration) was investigated, 
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drug loading efficiency increased three fold to 75% (Figure 2A).  This loading efficiency 
(which was significantly higher than that found for MCM-41 (~40%)) was produced from a 
significantly lower silica yield (Table S2). The drug content also increased substantially from 
~10% for 1:1 to ~70% for 1:2.  This is likely due to a drug-amine interaction, suggesting that 
the amine can have a dual function of facilitating silica condensation as well as acting as a 
functionalisation agent to facilitate drug loading (see section 3.3 for further discussion).  These 
loading studies highlight that the synthetic conditions can readily modulate the loading 
efficiency of BIS and even reach loadings that are significantly higher than what is achievable 
with MCM-1. 
Finally, the release of ibuprofen from these samples was investigated and it was found that 
the overall release of ibuprofen from different silica varied.  BIS-PAH (1:1) released 22% of 
the loaded ibuprofen and 2:2 and 2:1 both achieved higher releases (45% and 50% 
respectively), which were greater than the 39% released from MCM-41 (Figure 2B & C).  It is 
possible that release was higher from 2:2 and 2:1 than 1:1 due to faster silica condensation 
since the silica precursor concentration used was doubled 59. This resulted in lower pore 
volumes and smaller pores (Figure 2D and S3B), leading to less drug being entrapped within 
the silica, remaining mainly as surface bound, making release easier.  In contrast, a 1:2 ratio 
released only 6% of loaded ibuprofen (Figure 2B), despite a very high loading efficiency and 
a larger pore size (Figure 2D & S3B).  
When the release profiles were considered (Figure S3A), all but the 2:1 samples exhibited 
burst release, where the majority of drug was released over the first five hours and very little 
release was observed after this point (Table S2). This suggests that the ibuprofen that is able to 
escape is mainly surface bound and any ibuprofen embedded within the silica particles is 
trapped and unable to be released.  This idea is supported by Figure S3A where all the BIS 
release profiles were similar to the release profile of MCM-41, which only had surface bound 
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ibuprofen loaded.  However, the 1:2 system had a much lower maximum release rate than the 
other systems (Table S2) as well as low total release (Figure 2B).  Table S2 also shows that the 
mass of ibuprofen released from all the BIS systems were higher than from MCM-41, some 
BIS samples releasing 5x more drug per weight of silica than MCM-41.  This is important since 
if more mg of drug is released then less silica will need to be administered to a patient. 
3.3. Understanding additive-drug interactions to control DDS formulation. 
Ibuprofen contains a carboxylic acid group, which is expected to interact with amines.  
Several studies have exploited these favourable amine-ibuprofen interactions by post-
synthetically functionalising MS 41-43,58. In addition, from the results presented above, there 
was an indication that the PAH-ibuprofen interactions are important for the drug loading and 
release. Therefore, we investigated whether drug loading and release could be controlled by 
tuning PAH-ibuprofen interactions by varying the synthesis pH (and in turn the protonation).  
In this study silica was usually formed at pH 7 since silica formation is the quickest at neutral 
pH for this synthesis method 40,59.  BIS will not readily form outside the pH ranges of pH 5-9, 
hence we have focused on exploring drug loading under this pH range and monitored the effect 
of formulation pH on the drug release (Figure 3). 
When silica was condensed at S+, the loading efficiency was not altered (remaining at 
~20%, Figure 3A).  When synthesis pH was more acidic, on the other hand, ibuprofen loading 
efficiency could be enhanced up to three times, to 60%, at pH 5.  A similar picture was observed 
for the drug content (wt %) shown in Figure 3A.  The release for samples formulated at pH 7 
was similar (Figure 3C & Table S3), whereas DDS formulated at pH had greatly diminished 
release.  It should be noted that all release experiments were carried out in PBS at pH 7.2.  
Interestingly, despite the higher drug loading at pH5, there was not a correspondingly higher 
release observed when compared with DDS formulated at pH7 (Figure 3 B).  Despite this, the 
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total ibuprofen (mg) released per weight of silica was 10 times higher for the pH 5 sample than 
MCM-41 (Figure 3D) 
When release was plotted as a fraction of total release over time, two different release 
profiles became apparent (Figure 3C).  BIS-PAH synthesised at pH exhibited similar burst 
release profile observed for BIS samples reported above (also evident from high release rates, 
Table S3), where the majority of ibuprofen was released from the silica in the first 5 hours and 
very little was released after this.  This burst release profile was similar to that seen for MCM-
41, suggesting that the main mechanism for release in these systems was release from the 
surface.  However, silica synthesised at pH >7 appeared to have a slow and sustained release 
profile, which was also reflected in slow release rates (Table S3).  Release did not plateau for 
24 hours and ibuprofen maintained a slow release over the course of the experiment.  This slow 
release suggested that the loaded ibuprofen was embedded within the silica rather than bound 
to the surface, making release more prolonged.  While the total amount of ibuprofen released 
from these samples under the 24 hour observation window was low, this system does show 
some promise as a prolonged release system. 
It is clear from the results presented that the DDS formulation pH controlled the loading 
and release of ibuprofen.  This could be caused by differences in porosity, morphology and/or 
additive-drug interaction.  SEM results suggested that pH did not have a significant effect on 
the morphology or the particle sizes of DDS (Figure S 2A & B). When surface area and pore 
volume were measured for BIS-PAH DDS formulated at different pH conditions, there were 
no significant differences observed (Figure 3E & S4).  The differences in ibuprofen loading in 
these systems can then likely be attributed to the ionisation of the three components present 
(silica, amine additive and drug) in the reaction mixture as well as the silica formation 
pathways.  A scheme showing how the proportions of ionised reactants vary as the reactant pH 
is altered can be seen in Figure 4 and Table S4.  The results here suggest that the negative 
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charge on silica can have an inhibitory effect on loading efficiency.  Both the silica surface and 
ibuprofen are negatively charged at pH  (Table S4) and so silica and drug will repel one 
DQRWKHUWKXVH[SODLQLQJORZORDGLQJHIILFLHQFLHVDWS+ (only ~20% of ibuprofen was loaded 
under these conditions, Figure 3A and Table S3).  With DDS formulations prepared under 
acidic conditions, and particularly at pH5, the silica and ibuprofen both are significantly less 
charged, thus allowing for ibuprofen to be more efficiently loaded (30-60% of ibuprofen was 
loaded under acidic conditions, Figure 3A and Table S3).  
It is clear that pH has a drastic effect on the loading efficiency of ibuprofen into BIS, with 
more acidic conditions resulting in increased loading.  There is also strong evidence of an 
amine-drug interaction playing a major role in the ability of BIS to load drug.  This interaction, 
when too strong, can also inhibit drug release. 
3.4. Biocompatibility of BIS 
 Due to ease and non-invasive nature of administration, oral delivery of drugs is the most 
preferred route for patients 60.  Silica is an ideal material for oral drug delivery due to its 
stability under the conditions found in the GI tract, especially the low pH found in the stomach 
(pH1-3) and so it is able to protect loaded drug molecules from the changes in pH as well as 
degradative enzymes and bile salts 61,62. While amine functionalisation is beneficial for drug 
loading and controlling release, exposure of amine-functionalised MS to cells has been reported 
to result in a higher cytotoxicity40, higher level of plasma membrane damage,  and  higher 
haemolytic activity52.  BIS were reported to be either non-cytotoxic, toxic only at extremely 
high concentrations, or when internalised into activated macrophages40.  In order to further 
improve our understanding of BIS, it is important to uncover the fate of orally administered 
silica.   
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A simple and effective experiment was set up using sections of rat gut and measuring the 
movement of fluorescently tagged BIS-PAH (FITC-BIS-PAH) across the gut wall over an 
hour.  FITC-BIS-PAH was synthesised using FITC-tagged PAH, so that its movement through 
the gut wall could be measured.   We observed that ~22% of silica moved across the gut wall 
during the hour long incubation (Figure 5).  This movement was through passive diffusion 
since it was not affected by the addition of an inhibitor of active transport (DNP).   To further 
observe the movement of silica particles through the gut wall, fluorescence microscopy images 
of the inner and outer surfaces of the rat gut were taken (Figure 5).  It is clear that when no 
silica is present there are no defined points of fluorescence but in the gut sections exposed to 
silica and silica with DNP, defined points of silica are observed.  Silica was clearly localised 
on both sides of the gut wall, confirming its movement.  Due to the ability of BIS-PAH to pass 
through the gut wall, it became important to investigate its biocompatibility with other cell 
types, particularly red blood cells (RBC).   
 The effect of BIS on RBC was determined through haemolytic activity of BIS, when 
exposed to red blood cells (RBC).  Figure 6 shows that BIS-PAH had very low haemolytic 
activity, only lysing 2% of RBC at the highest concentration used (500 µg/ml) and only 0.6% 
lysis at the concentration which passed through the gut wall (~250 µg/ml).  MCM-41 exhibited 
a higher haemolytic activity, rising to 10% at 500 µg/ml.  The reasons behind this difference 
are initially unclear but may be related to the size of the particles.  It has been reported that 
silica particle size affects haemolysis 63.  BIS-PAH particles were spherical (78±18 nm in 
diameter, S2A & B) and significantly smaller than the irregular MCM-41 particles used 
(3340±1013 nm in diameter), which could partly explain the difference in haemolytic activity 
between BIS and MCM-41. SEM data also show that although BIS primary particles were <100 
nm, they form micron sized agglomerates and rapidly precipitate (hence DLS was not 
possible/useful). It is thus expected that BIS particles are as toxic as MCM-41 simply based on 
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their sizes, but this was not observed.  Although further work is required on BIS to fully 
understand their biocompatibility, our present and previous results show that BIS are more 
biocompatible when compared to MS.  
 
 
4. CONCLUSIONS  
Our primary aim was to develop an in situ drug loading and release system using 
bioinspired silica (BIS).  The BIS system can be controlled using many factors such as the 
choice of amine additive, pH of synthesis, kinetics of synthesis and eventual location of drug 
within the silica (Figure 7). Our results identified that the ideal formulation would be BIS-PAH 
synthesised with a reactant ratio of 2:2.  Formulation under acidic pH was found to be suitable 
for designing DDS for faster targeted release, while basic pH was preferred for sustained 
release (Figure 7). Although a small portion of BIS-PAH was able to pass through the gut wall 
into the blood stream, due to its low haemolytic activity that does not appear to be an issue, in 
contrast to MCM-41.  Ultimately, BIS appears to have several advantages over MCM-41 (such 
as one step formulation, simple controllability and lack of hazardous chemicals) and it was 
found that BIS has similar or improved drug loading and release profiles to MCM-41, in 
addition to superior biocompatibility.  These benefits give BIS real potential as a viable DDS 
to be further investigated.  We believe that the understanding of the DDS formulation using 
BIS that has emerged from this work can enable the discovery and development of a wide 
variety of DDS. 
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7. ABBREVIATIONS 
BIS, Bio-inspired silica; BIS-PAH, bio-inspired silica synthesised with poly(allylamine 
hydrochloride); CTAB, hexadecyltrimethylammonium bromide;  DDS, drug delivery system; 
DETA, diethylenetriamine; DLS, dynamic light scattering; DNP, dinitrophenol; D-PBS, 
'XOEHFFR¶VSKRVSKDWHEXIIHUHGVDOLQH HPLC, high pressure liquid chromatography; MCM-41,  
Mobil Composition of Matter No. 41; MS, mesoporous silica; PAH, poly(allylamine 
hydrochloride); PAH-FITC, poly(fluorescein isothiocyanate allyamine hydrochloride); PBS, 
phosphate buffered saline;  PEHA, pentaethylenehexamine; RBC, red blood cell; SBA-
15,  Santa Barbara Amorphous type material 15;  SEM, scanning electron microscope; TEOS, 
tetraethoxysilane;  TEPA, tetraehylenepentamine; UV, ultraviolet.  
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D Surface area 
(m²/g) 
Pore 
volume 
(cm³/g) 
Pore 
size 
(nm) 
BIS-DETA 16 0.095 * 
BIS-TEPA 33 0.095 * 
BIS-PEHA 36 0.131 * 
BIS-PAH 129 0.91 23 
MCM-41 983 0.74 2 
 
Figure 1 :- BIS synthesised with different amines (A) % loading efficiency and % drug content (wt/wt) of 
ibuprofen loaded into four different BIS and MCM-41, (B) The % release of loaded ibuprofen from four 
different BIS and MCM-1, (C) Total mass of ibuprofen (mg) released from 10mg of silica sample, (D)  Surface 
area, pore volume and pore size figures for four different BIS and MCM-41 (* due to broad pore size 
distributions, specific pore sizes are not applicable). For A, B and C, n=3, error bars represent one standard 
deviation.  For D, n=1.  
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Figure 2: - Effect of reactant concentrations on the loading and release profiles of ibuprofen (A) % loading efficiency 
and % drug content (wt/wt) of ibuprofen laoded into BIS synthesised with different reactant ratios and MCM-41  (B) 
The % release of loaded ibuprofen from four different BIS and MCM-41, (C) Total mass of ibuprofen (mg) released 
from 10mg of silica sample, (D) Surface area, pore volume and pore size figures for BIS synthesised with different 
reactant concentrations and MCM-41.   For A-C, n=3, error bars represent one standard deviation.  For D, n=1. 
D Surface area 
(m²/g) 
Pore 
volume 
(cm³/g) 
Pore 
size 
(nm) 
2:2 157 0.73 15.9 
2:1 180 0.531 11.3 
1:1 129 0.91 23 
1:2 76 0.69 28.94 
MCM-41 983 0.74 2 
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Figure 3: - Effect of reaction pH on the loading and release profiles of ibuprofen (A) % loading efficiency and 
% drug content (wt/wt) of ibuprofen loaded into BIS synthesised at different pH and MCM-41, (B) The % 
release of loaded ibuprofen from silica, (C) Release of loaded ibuprofen expressed as a % of final concentration 
released from BIS synthesised at a range of pH, (D) Total mass of ibuprofen (mg) released from 10mg of silica 
sample, (E) ) Surface area, pore volume and pore size figures for BIS synthesised at different pH and MCM-41.  
For A, B and D, n=3, error bars represent one standard deviation.  For C and E, n=1.  
 
E Surface area 
(m²/g) 
Pore 
volume 
(cm³/g) 
Pore 
size 
(nm) 
5 142 0.60 21 
6 149 0.67 21 
7 129 0.91 23 
8 161 0.84 25 
9 140 0.68 25 
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Figure 4:- Scheme to illustrate the differences in charge of silica, amine and ibuprofen during synthesis at pH 
ranging from 9 to 5. 
30 
 
 
 
 
Figure 5:- Light and FITC microscopy images of the inside and outside surfaces of rat gut incubated with no 
silica (control), fluorescent silica or fluorescent silica and DNP.  Images taken using Carl Zeiss Axio Imager Z1 
with 10x/0.30 lens 
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Figure 6:± Percentage haemolysis induced by varying concentrations of BIS-PAH and MCM-41 after 1 hour 
incubation with red blood cells.  n=3, error bars represent one standard deviation 
 
 
 
Figure 7:- Schematic summary of results presented in this paper. 
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